Article
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
The pharmacogenomics journal - 1 Apr 2011
Leskelä S, Jara C, Leandro-García L J, Martínez A, García-Donas J, Hernando S, Hurtado A, Vicario J C C, Montero-Conde C, Landa I, López-Jiménez E, Cascón A, Milne R L, Robledo M, Rodríguez-Antona C
Abstract excerpt
Neurotoxicity is one of the most relevant dose-limiting toxicities of the anticancer drug paclitaxel. It exhibits substantial interindividual variability of unknown molecular basis, and represents one of the major challenges for the improvement of paclitaxel therapy. The extensive variability in paclitaxel clearance and metabolism lead us to investigate the association between polymorphisms in paclitaxel...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.